BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 32883032)

  • 1. Targeting Signaling Pathways in Inflammatory Breast Cancer.
    Wang X; Semba T; Phi LTH; Chainitikun S; Iwase T; Lim B; Ueno NT
    Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32883032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.
    Jhaveri K; Teplinsky E; Silvera D; Valeta-Magara A; Arju R; Giashuddin S; Sarfraz Y; Alexander M; Darvishian F; Levine PH; Hashmi S; Zolfaghari L; Hoffman HJ; Singh B; Goldberg JD; Hochman T; Formenti S; Esteva FJ; Moran MS; Schneider RJ
    Clin Breast Cancer; 2016 Apr; 16(2):113-22.e1. PubMed ID: 26774497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The tumor microenvironment and inflammatory breast cancer.
    Huang A; Cao S; Tang L
    J Cancer; 2017; 8(10):1884-1891. PubMed ID: 28819386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deciphering the role of interferon alpha signaling and microenvironment crosstalk in inflammatory breast cancer.
    Provance OK; Lewis-Wambi J
    Breast Cancer Res; 2019 May; 21(1):59. PubMed ID: 31060575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toward precision medicine in inflammatory breast cancer.
    Viale G; Marra A; Curigliano G; Criscitiello C
    Transl Cancer Res; 2019 Oct; 8(Suppl 5):S469-S478. PubMed ID: 35117125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammatory breast cancer biology: the tumour microenvironment is key.
    Lim B; Woodward WA; Wang X; Reuben JM; Ueno NT
    Nat Rev Cancer; 2018 Aug; 18(8):485-499. PubMed ID: 29703913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.
    Liang X; Vacher S; Boulai A; Bernard V; Baulande S; Bohec M; Bièche I; Lerebours F; Callens C
    Breast Cancer Res; 2018 Aug; 20(1):88. PubMed ID: 30086764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers for Inflammatory Breast Cancer: Diagnostic and Therapeutic Utility.
    Dobiasova B; Mego M
    Breast Cancer (Dove Med Press); 2020; 12():153-163. PubMed ID: 33116817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.
    Ibrahim SA; Gadalla R; El-Ghonaimy EA; Samir O; Mohamed HT; Hassan H; Greve B; El-Shinawi M; Mohamed MM; Götte M
    Mol Cancer; 2017 Mar; 16(1):57. PubMed ID: 28270211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological and molecular characteristics of inflammatory breast cancer.
    Di Bonito M; Cantile M; Botti G
    Transl Cancer Res; 2019 Oct; 8(Suppl 5):S449-S456. PubMed ID: 35117122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory breast cancer: The pathologists' perspective.
    Cserni G; Charafe-Jauffret E; van Diest PJ
    Eur J Surg Oncol; 2018 Aug; 44(8):1128-1134. PubMed ID: 29706301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinically relevant inflammatory breast cancer patient-derived xenograft-derived ex vivo model for evaluation of tumor-specific therapies.
    Eckhardt BL; Gagliardi M; Iles L; Evans K; Ivan C; Liu X; Liu CG; Souza G; Rao A; Meric-Bernstam F; Ueno NT; Bartholomeusz GA
    PLoS One; 2018; 13(5):e0195932. PubMed ID: 29768500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations.
    Ross JS; Ali SM; Wang K; Khaira D; Palma NA; Chmielecki J; Palmer GA; Morosini D; Elvin JA; Fernandez SV; Miller VA; Stephens PJ; Cristofanilli M
    Breast Cancer Res Treat; 2015 Nov; 154(1):155-62. PubMed ID: 26458824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors.
    Hamm CA; Moran D; Rao K; Trusk PB; Pry K; Sausen M; Jones S; Velculescu VE; Cristofanilli M; Bacus S
    Mol Cancer Ther; 2016 Jul; 15(7):1746-56. PubMed ID: 27196778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory Breast Cancer Promotes Development of M2 Tumor-Associated Macrophages and Cancer Mesenchymal Cells through a Complex Chemokine Network.
    Valeta-Magara A; Gadi A; Volta V; Walters B; Arju R; Giashuddin S; Zhong H; Schneider RJ
    Cancer Res; 2019 Jul; 79(13):3360-3371. PubMed ID: 31043378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying the impact of inflammatory breast cancer on survival: a retrospective multi-center cohort study.
    Diessner J; Van Ewijk R; Weiss CR; Janni W; Wischnewsky MB; Kreienberg R; Hancke K; Blettner M; Wöckel A; Schwentner L
    Arch Gynecol Obstet; 2015 Sep; 292(3):655-64. PubMed ID: 25814296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-8 and MCP-1/CCL2 regulate proteolytic activity in triple negative inflammatory breast cancer a mechanism that might be modulated by Src and Erk1/2.
    Mohamed HT; El-Ghonaimy EA; El-Shinawi M; Hosney M; Götte M; Woodward WA; El-Mamlouk T; Mohamed MM
    Toxicol Appl Pharmacol; 2020 Aug; 401():115092. PubMed ID: 32512068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells.
    Salem I; Alsalahi M; Chervoneva I; Aburto LD; Addya S; Ott GR; Ruggeri BA; Cristofanilli M; Fernandez SV
    Breast Cancer Res; 2016 Mar; 18(1):37. PubMed ID: 27009091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of Bone Metastasis in Inflammatory Breast Cancer Using a Markov Chain Model.
    Fujii T; Mason J; Chen A; Kuhn P; Woodward WA; Tripathy D; Newton PK; Ueno NT
    Oncologist; 2019 Oct; 24(10):1322-1330. PubMed ID: 30952823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.
    Iwase T; Harano K; Masuda H; Kida K; Hess KR; Wang Y; Dirix L; Van Laere SJ; Lucci A; Krishnamurthy S; Woodward WA; Layman RM; Bertucci F; Ueno NT
    BMC Cancer; 2020 May; 20(1):430. PubMed ID: 32423453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.